Apnimed files NDA for OSA drug Oxnimbi ahead of $221m Nasdaq IPO
Apnimed has reported a pivotal quarter that combined a regulatory filing, a major fundraise, and a stock market listing, setting the company up for what could be the first approved oral pharmacological therapy for obstructive sleep apnoea (OSA).
The FDA accepted Apnimed's New Drug Application for AD109, to be marketed under the proposed proprietary name Oxnimbi, and assigned a PDUFA target action date of 28 February 2027. The Cambridge, Massachusetts company simultaneously completed an upsized initial public offering on the Nasdaq Global Select Market, raising gross proceeds of $220.8 million from the sale of 13.8 million shares at $16.00 apiece. Common stock began trading under the ticker APMD on 31 July 2026.
The drug and its mechanism
Oxnimbi is a fixed-dose oral combination of aroxybutynin, described as a novel antimuscarinic, and atomoxetine, a selective norepinephrine reuptake inhibitor. The compound is designed to stabilise upper airway musculature during sleep, targeting the neuromuscular dysfunction that underlies airway collapse in OSA rather than acting as a simple sedative or airflow device. It is intended as a once-daily pill taken at bedtime.
The NDA is supported by two completed Phase 3 trials, SynAIRgy and LunAIRo, which between them constitute one of the larger clinical development programmes conducted for an OSA pharmacotherapy. Pooled analyses from those trials were presented at the ATS 2026 and SLEEP 2026 conferences during the quarter, and full results from SynAIRgy were simultaneously published in the American Journal of Respiratory and Critical Care Medicine.
Chief executive Kevin Lind, who joined as part of a planned leadership transition alongside new chief financial officer Michael Kelly and chief legal officer Steven Spector, said the company was advancing commercial readiness activities in preparation for a potential US launch. Apnimed estimates approximately 80 million people in the United States are living with OSA, with a substantial proportion remaining untreated or reliant on continuous positive airway pressure (CPAP) devices.
Market context and competitive landscape
OSA is a large and historically underserved market. Device-based therapy via CPAP is effective but suffers from poor long-term adherence, and surgical options carry procedural risk. The absence of an approved oral pharmacotherapy has left a gap that several companies have attempted to fill over the past decade, largely without success. Apnimed's combination approach, if approved, would represent a novel mechanism relative to existing treatments.
The closest comparator currently in late-stage development is Eli Lilly's tirzepatide, which has shown improvements in OSA severity as a secondary benefit in its obesity trials rather than as a primary OSA mechanism; the regulatory and commercial dynamics differ substantially from Apnimed's neuromuscular approach.
Apnimed also secured a senior secured credit facility of up to $150 million with HealthCare Royalty Partners and generated $100 million from the strategic sale of its interest in Shionogi-Apnimed Sleep Science, providing substantial combined resources for a US commercial build-out. The company reported a net income of $125.9 million for the second quarter of 2026, though this figure was driven largely by one-time gains on the Shionogi transaction and a reversal of a deposit liability rather than by recurring operating performance.
With the PDUFA date set for late February 2027, investors will be focused on any FDA advisory committee convening, label negotiations around efficacy claims, and the company's progress in establishing payer coverage pathways for what would be a first-in-class oral OSA agent.